This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
AllScripts Healthcare (MDRX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of -35.71% and -1.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoom Video, Capri, Teladoc Health, Allscripts Healthcare Solutions and Masimo highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Zoom Video, Capri, Teladoc Health, Allscripts Healthcare Solutions and Masimo highlighted as Zacks Bull and Bear of the Day
Coronavirus Puts Digital Health in Focus: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three stocks that are focusing on digital health to fight against coronavirus.
Here's Why You Should Retain Allscripts in Your Portfolio Now
by Zacks Equity Research
Investor confidence remains high in Allscripts' (MDRX) stock, thanks to solid prospects.
AllScripts (MDRX) Down 3.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts Offers Telehealth Support Amid Coronavirus Outbreak
by Zacks Equity Research
Allscripts (MDRX) offers simplified telehealth implementation to health systems through FollowMyHealth to provide telehealth visit capabilities to their patients quickly.
Allscripts' Veradigm Business Line Unveils New Solution
by Zacks Equity Research
Allscripts' (MDRX) Veradigm business line introduces new solution that will drive growing medication adherence and improve patient care.
Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.
AllScripts Healthcare (MDRX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of -5.56% and -1.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?